Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells $75,525.00 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,928,605.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Amicus Therapeutics Stock Down 0.3 %

FOLD stock opened at $10.40 on Monday. The company’s 50 day simple moving average is $11.55 and its 200-day simple moving average is $12.00. The firm has a market capitalization of $3.08 billion, a PE ratio of -20.39 and a beta of 0.80. Amicus Therapeutics, Inc. has a 12 month low of $9.70 and a 12 month high of $14.57. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $115.08 million during the quarter, compared to analyst estimates of $115.11 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. Equities analysts expect that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently bought and sold shares of FOLD. Exchange Traded Concepts LLC boosted its position in Amicus Therapeutics by 248.6% during the third quarter. Exchange Traded Concepts LLC now owns 21,373 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 15,242 shares during the last quarter. Handelsbanken Fonder AB boosted its position in Amicus Therapeutics by 5.5% during the third quarter. Handelsbanken Fonder AB now owns 47,841 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 2,500 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Amicus Therapeutics by 0.5% during the third quarter. Bank of New York Mellon Corp now owns 1,182,107 shares of the biopharmaceutical company’s stock worth $14,374,000 after acquiring an additional 5,808 shares during the last quarter. Brown Advisory Inc. boosted its position in Amicus Therapeutics by 36.5% during the third quarter. Brown Advisory Inc. now owns 45,985 shares of the biopharmaceutical company’s stock worth $559,000 after acquiring an additional 12,285 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Amicus Therapeutics by 11.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,327 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 4,508 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, February 29th. JPMorgan Chase & Co. cut their price target on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.